Company Overview
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.
Why Investors Should Care
Net profit has compounded at 29.5% per year over the last five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.06B (+2.4% YoY); net profit $-4.60M.
- Trailing 12 Months Year-on-year growth — revenue +1.9%, earnings +2.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.3%, profit CAGR 29.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.35% |
| 1 Year: | 1.90% |
Compounded Profit Growth
| 5 Years: | 29.54% |
| 1 Year: | 2.90% |
Stock Price Performance
| 1 Year: | - |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 29.5% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -0.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EHAB EHAB R2KPHARMA | 13.80 | -197.14 | $706.91M | 0.00% | 3.40% | -0.19% | -0.35% | 29.54% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 259.90M | 266.10M | 263.60M | 270.40M | 264.80M |
| Cost of Revenue | - | - | 130.20M | 135.50M | 135.80M | 138.70M | 134.20M |
| Gross Profit | - | - | 129.70M | 130.60M | 127.80M | 131.70M | 130.60M |
| Operating Expenses | - | - | 113.80M | 113.90M | 111.00M | 117.30M | 101.30M |
| Operating Income | - | - | 15.90M | 16.70M | 16.80M | 14.40M | 29.30M |
| EBITDA | - | - | 41.50M | 22.40M | 22.20M | -28.20M | 37.60M |
| Interest Expense | - | - | 9.40M | 8.70M | 8.30M | 7.60M | 10.00M |
| Pretax Income | - | - | 25.80M | 8.00M | 8.40M | -40.80M | 23.00M |
| Tax Provision | - | - | 7.40M | 2.30M | -3.20M | -2.50M | 3.10M |
| Net Income | - | - | 17.80M | 5.20M | 11.10M | -38.70M | 19.20M |
| Diluted EPS | - | - | 0.35 | 0.10 | 0.22 | -0.76 | 0.37 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.07B | 1.05B | 1.03B | 1.06B |
| Cost of Revenue | - | 525.60M | 535.60M | 530.80M | 540.20M |
| Gross Profit | - | 545.50M | 510.70M | 504.00M | 519.80M |
| Operating Expenses | - | 447.90M | 472.50M | 457.40M | 456.00M |
| Operating Income | - | 97.60M | 38.20M | 46.60M | 63.80M |
| EBITDA | - | 22.50M | -16.50M | -83.60M | 57.90M |
| Interest Expense | - | 15.00M | 43.00M | 42.90M | 34.00M |
| Pretax Income | - | -25.50M | -90.40M | -158.00M | 1.40M |
| Tax Provision | - | 12.80M | -11.40M | -4.00M | 4.00M |
| Net Income | - | -40.40M | -80.50M | -156.20M | -4.60M |
| Diluted EPS | 2.23 | 1.26 | -1.61 | -3.11 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.53B | 1.43B | 1.23B | 1.17B |
| Current Assets | - | 211.80M | 210.10M | 192.70M | 205.60M |
| Cash & Equivalents | - | 22.90M | 27.40M | 28.40M | 43.60M |
| Inventory | - | - | - | - | - |
| Receivables | - | 149.60M | 164.70M | 149.20M | 144.00M |
| Total Liabilities | - | 751.50M | 731.90M | 672.10M | 603.00M |
| Current Liabilities | - | 132.90M | 137.70M | 126.20M | 126.30M |
| Long Term Debt | - | 560.00M | 530.10M | 492.60M | 426.00M |
| Total Debt | - | 625.20M | 610.10M | 569.50M | 500.00M |
| Total Equity | - | 741.70M | 669.70M | 523.50M | 534.00M |
| Shares Outstanding | - | 50.10M | 50.17M | 50.59M | 51.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 80.10M | 48.40M | 51.20M | 70.70M |
| Investing Cash Flow | - | -42.30M | -5.30M | -2.40M | 16.70M |
| Financing Cash Flow | - | -18.60M | -40.50M | -48.30M | -72.20M |
| Capital Expenditure | - | -7.10M | -3.50M | -3.80M | -4.90M |
| Free Cash Flow | - | 73.00M | 44.90M | 47.40M | 65.80M |
| Net Change in Cash | - | 19.20M | 2.60M | 500.00K | 15.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 50.9% | 48.8% | 48.7% | 49.0% |
| Operating Margin % | - | 9.1% | 3.7% | 4.5% | 6.0% |
| Net Margin % | - | -3.8% | -7.7% | -15.1% | -0.4% |
| ROE % | - | -5.4% | -12.0% | -29.8% | -0.9% |
| ROCE % | - | 7.0% | 2.9% | 4.2% | 6.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EHAB
How The Enhabit (EHAB) Story Is Shifting Toward Kinderhook’s US$13.80 Cash Deal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSkFMVmxYYjhBMG9LczQ1VHd1ZWN6U2E4UEtNcGZHSU9FbjZTYVM5V3J1RVFWNGVMOWxON2VVelZqZzZqV1poNW9lUkZST3RLZGhQRmdxQ0pfblFxQkFyQ3VkZmZnMDllelJSMERmelNraDdZWHRwNHNOVDBmbkswVVgybDBpQl96Y0xRN1…
Enhabit Acquired by Kinderhook, Transitions to Private Ownership - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQbHRNZmVwN2J5d0tEZUpBWXZSNkx2Z0MyNFNMckhzUmJLemh0eTVaNVZDWEc4MWFRUWR3Qk1HWk92TTZXbTNab3p5Sl9JZVVwZ2R6dFN1YlJQQVU1SVJCV3U0UTJSZG9hV2dtV3V4T25jYnU5SlAzVlYyckVwSjFIRFkwd2VOUkdEWXhHN0…
[UPDATED] Kinderhook Industries To Acquire Enhabit For $1.1B - Home Health Care News
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPMVA5cjhZeVlQc1FZRUZsVGpWVWNrbzdPRE5yQjVTb3IwMmlvc2FLRzFtOTNuTFdpaVhjWFVoU3JQU0lxYkZ3NkhtRDdTQVpaV1Rkc1pGRFZjcmxMb1gzRzE1TGNpNUJjQ0J0UE1JM1c5T1NyLUw0UF9odlVCODRVbGt6ajBLQUVOWkw3aW…
Fast-paced Momentum Stock Beazer (BZH) Is Still Trading at a Bargain - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNU3hqUS0tVlBzTUQ0SERRWjZBUTRqTFFJbEtiQmdSNjNpbkZTdU9mdmZTeS1UeTZjLVdqS05FOHdkdkV0ejFWOS1DSnBHMWt6SlMxWlpEUWdfVElaNHN3QTBxMWRHc2FhZ1ppT0dhX1JBXzhaY1V5bkh1X3pBLW9JTi14Y2lqbmlZZ2VuYX…
Enhabit Completes Previously Announced Acquisition by Kinderhook Industries to Become a Private Company - Business Wire
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOeU9vMGxSYnAxTDZPcDlmWUEwNTZxTzdBcEd1N2JPMEE2SlVBeWY4OUdDRWQ0NWtPRE83RndZX3NzRW83VTJxQmtJWVZRNzNESFZzQ2VNZlpjWEpWVU10VjJnUHZCMzBWbVdjbFJHaDEybGt2SEpRQm12VzNBQXNSSDJqejJWRHBCWWYwWF…
Enhabit - EHAB - Stock Price & News - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE55YkRyQmRvQlVrMi14WW1FUURRRy1Td3JvUFNpdWo1cmd6a1dQanV3TmtWOUpxeWgtVVgySGhzcllQeGJoTDQzSktWQ2o3Zw?oc=5" target="_blank">Enhabit - EHAB - Stock Price & News</a> <font colo…
EHAB — Frequently Asked Questions
What is the current share price of EHAB?
As of 2026-10-23 16:27 PDT, EHAB trades at $13.80 on NYQ. Its 52-week range is $13.80 to $13.80.
What is the market capitalisation of EHAB?
EHAB has a market capitalisation of $706.91M on NYQ.
What is the P/E ratio of EHAB?
EHAB trades at a trailing price-to-earnings (P/E) ratio of -197.14. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.31.
What is the return on equity (ROE) of EHAB?
EHAB has a return on equity (ROE) of -0.19%. Its return on capital employed (ROCE) is 3.40%.
Is EHAB a good stock to buy?
This page provides a data-driven analysis of EHAB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.